Investor Presentaiton

Since the launch of the Plan: Opioid dispensing has decreased by 24% Buprenorphine dispensing has increased 15% Uninsured and Medicaid beneficiaries who have received opioid use disorder treatment has increased by 20% Buprenorphine is an FDA-approved medication for the treatment of opioid use disorder.

View entire presentation